Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Non-metastatic NSCLC and other thoracic malignancies

5050 - Analysis of immunoregulatory biomarkers in early stages of Non-Small Cell Lung Cancer

Date

11 Sep 2017

Session

Non-metastatic NSCLC and other thoracic malignancies

Presenters

Andrea Moreno Manuel

Citation

Annals of Oncology (2017) 28 (suppl_5): v453-v456. 10.1093/annonc/mdx381

Authors

A. Moreno Manuel1, S. Calabuig Fariñas2, A. HERREROS POMARES1, S. Gallach Garcia3, F. Aranda4, A. Blasco5, E. Carreras4, F. Lozano6, A. Cunquero Tomas7, M. Martorell8, E. Jantus-Lewintre9, C. Camps Herrero10

Author affiliations

  • 1 Laboratorio De Oncología Molecular, Fundación para la Investigación, Hospital General Universitario de Valencia, 46014 - Valencia/ES
  • 2 Laboratorio De Oncología Molecular, Fundación Para La Investigación, Hospital General Universitario De Valencia - Ciberonc;, Departamento de Patología, Universitat de València, 46014 - Valencia/ES
  • 3 Laboratorio De Oncología Molecular, Fundación de Investigación Hospital General Universitario de Valencia-CIBERONC, 46014 - Valencia/ES
  • 4 Immunoreceptors Of The Innate And Adaptative System, Institut d’Investigacions Biomèdiques August Pi i Sunyer, 08036 - Barcelona/ES
  • 5 Servicio De Oncología Médica, Hospital General Universitario de Valencia-CIBERONC, 46014 - Valencia/ES
  • 6 Servei D’immunologia, Centre De Diagnòstic Biomèdic, Hospital Clínic De Barcelona, Immunoreceptors of the Innate and Adaptive System, Institut d’Investigacions Biomèdiques August Pi i Sunyer; Departament de Biomedicina, Facultat de Medicina, Universitat de Barcelona., 08036 - Barcelona/ES
  • 7 Servicio De Oncología Médica, Hospital General Universitario de Valencia, 46014 - Valencia/ES
  • 8 Servicio De Anatomía Patológica, Hospital General Universitario De Valencia;, Departamento de Patología, Universidad de Valencia, 46014 - Valencia/ES
  • 9 Laboratorio De Oncología Molecular, Fundación Para La Investigación, Hospital General Universitario De Valencia - Ciberonc;, Departamento de Biotecnología, Universidad Politécnica de Valencia, 46014 - Valencia/ES
  • 10 Laboratorio De Oncología Molecular, Fundación Para La Investigación, Hospital General Universitario De Valencia - Ciberonc;, Servicio de Oncología Médica, Hospital General Universitario de Valencia; Departamento de Medicina, Universidad de Valencia;, 46014 - Valencia/ES
More

Resources

Abstract 5050

Background

The study of the tumour microenvironment is leading to a better understanding of the evasion of immune surveillance and the development of new therapies. This research focuses on the analysis of immunoregulatory genes as potential prognostic biomarkers in resectable non-small cell lung cancer (NSCLC).

Methods

The expression of 8 genes involved in immune-regulation (PD-L1, PD-L2, IDO-1, IDO-2, ICOS-LG, CD5, CD6 and CD200) was analysed by RTqPCR in 257 paired fresh frozen tumour and normal tissue samples of resected NSCLC. Relative expression was calculated by Pfaffl formulae using ACTB, CDKN1B and GUSB as endogenous controls. Non-parametric tests were used for correlations between clinico-pathological and analytical variables and survival was assessed by Kaplan-Meier curves (long rank-test), considering significant p 

Results

Patient`s median age was 64 years, 82% were males, 88% were former or current smokers, 47% were adenocarcinomas (ADC). Patients with higher expression of CD5 and IDO2 had a significant increase in overall survival (OS, 53.3 vs NR months, p = 0.032; 51.9 vs NR months, p = 0.049, respectively). A signature combining the expression of CD5 and IDO2 was able to better prognosticate survival (40.4 vs NR months, p = 0.028). The multivariate analysis (including clinico-pathological and analytical variables) showed that this signature has independent prognostic information OS (HR = 0.553 [0.344-0.887], p = 0.016). Moreover, in the subgroup of ADC increased expression of CD5 and IDO2 was associated with longer OS as well as increased relapse-free survival (RFS, 19.1 vs NR months, p = 0.045; 18.8 and 67.0 months, p = 0.029, respectively). The multivariate analysis established this gene signature as an independent prognostic biomarker for OS (HR = 0.380 [0.166-0.872]; p = 0.026) and RFS (HR = 0.288 [0.139-0.597]; p = 0.002).

Conclusions

The analyses revealed the prognostic value of CD5 and IDO2, being their combination an independent prognostic marker in resectable NSCLC. Supported by grants from FEDER and PI12-02838 and PI15-00753 from ISCIII.

Clinical trial identification

Legal entity responsible for the study

Fundación para la Investigación del Hospital General Universitario de Valencia

Funding

Supported by grants from FEDER and PI12-02838 and PI15-00753 from ISCIII.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.